|3.||Coronary Artery Disease (Coronary Atherosclerosis)
|4.||Hypertension (High Blood Pressure)
|1.||Velazquez, Eric J: 19 articles (08/2015 - 11/2003)|
|2.||Zareba, Wojciech: 17 articles (07/2015 - 03/2002)|
|3.||Moss, Arthur J: 16 articles (07/2015 - 03/2002)|
|4.||Pitt, Bertram: 16 articles (09/2013 - 12/2002)|
|5.||Linde, Cecilia: 14 articles (09/2015 - 02/2006)|
|6.||Solomon, Scott D: 14 articles (11/2013 - 11/2003)|
|7.||Køber, Lars: 14 articles (08/2010 - 09/2003)|
|8.||McNitt, Scott: 13 articles (07/2015 - 06/2005)|
|9.||Pfeffer, Marc A: 13 articles (02/2011 - 11/2003)|
|10.||Bax, Jeroen J: 12 articles (01/2015 - 12/2002)|
|1.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
03/01/1999 - "It is likely that not only patients with significant reduction of systolic function but also other signs of impaired left ventricular dysfunction will benefit from treatment with ACE inhibitors. "
01/01/1996 - "It is likely that not only patients with significant reduction of systolic function but also other signs of impaired left ventricular dysfunction will benefit from treatment with ACE inhibitors. "
01/01/1995 - "Angiotensin-converting enzyme inhibitors (ACE inhibitors) have been shown to be effective in improving symptoms and survival in patients with systolic left ventricular dysfunction. "
08/01/1999 - "Although the precise mechanism of action of ACE inhibitors is still unresolved, the clinical efficacy of ACE inhibitors in the treatment of left ventricular dysfunction is well established. "
07/01/1998 - "In particular, widespread awareness of the importance of the renin-angiotensin system (RAS) has occurred since experimental and clinical studies have detailed the efficacy of angiotensin-converting enzyme inhibitors in reducing morbidity and mortality in patients with left ventricular dysfunction. "
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
11/01/2002 - "Angiotensin-converting enzyme (ACE) inhibition has been shown to be effective in reducing or preventing ischemic events in patients with and without left ventricular dysfunction, and in those at high risk for CAD. "
07/01/1992 - "Angiotensin converting enzyme (ACE) inhibition therapy is effective in reducing mortality and morbidity in severe left ventricular dysfunction and CHF. "
04/01/2008 - "I then show why the latter is an injudicious application of this statistical methodology, and illustrate this point with the example of an influential study in the biomedical literature that purported to demonstrate a lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction."
03/15/1999 - "This analysis was performed to assess whether beta-adrenergic blocking agent use is associated with reduced mortality in the Studies of Left Ventricular Dysfunction (SOLVD) and to determine if this relationship is altered by angiotensin-converting enzyme (ACE) inhibitor use. "
02/01/1995 - "Angiotensin-converting enzyme (ACE) inhibitor therapy has been associated with a substantial (> or = 20%) reduction in the risk of major ischemic events in two recent clinical trials with long-term follow-up: Studies of Left Ventricular Dysfunction (SOLVD) and the Survival and Ventricular Enlargement (SAVE) study. "
11/01/1994 - "Improvement in wall motion during dobutamine echocardiography and normal or mildly decreased uptake on thallium-201 scanning are strong predictors of reversible left ventricular dysfunction. "
12/01/2001 - "This study suggests that GI-Tl SPECT is superior to reinjection imaging and dobutamine echocardiography in predicting functional recovery after ischemic left ventricular dysfunction."
10/01/2007 - "Viability at dobutamine stress echocardiography independently predicts improved outcome following revascularization in non-diabetics as well as diabetic patients with ischaemic left ventricular dysfunction."
05/01/2005 - "Patients with severe left ventricular dysfunction and myocardial viability by dobutamine stress echocardiography (DSE) or F18-fluorodeoxyglucose-single-photon emission computed tomography (FDG-SPECT), experience improved survival after coronary revascularization. "
06/01/2000 - "Nine patients had left ventricular dysfunction unchanged compared with the initial measurement without viability in the territory of the left anterior descending artery with low dose dobutamine (group 1); thirty-two patients had improved or normal left ventricular ejection fraction with myocardial viability (group 2). "
|4.||Captopril (Capoten)FDA LinkGeneric
11/08/2004 - "The Survival and Ventricular Enlargement, a randomized, double-blind, placebo-controlled multicenter trial, evaluated the efficacy of captopril vs placebo in 2231 patients following acute MI with left ventricular dysfunction defined as an ejection fraction less than or equal to 40%. "
05/15/2008 - "Secondary analyses of large-scale clinical trials, such as the Captopril Prevention Project, the Heart Outcomes Prevention Evaluation, and the Studies of Left Ventricular Dysfunction trial, are revealing the potential benefits of these agents in diabetes prevention. "
06/01/1993 - "Clinical trials show a beneficial effect of the ACE inhibitor captopril on the prevention of left ventricular dysfunction. "
04/01/1993 - "Decisive for future therapeutic decision making are above all the results of the SAVE study which prefers captopril in patients with a yet asymptomatic left ventricular dysfunction. "
09/01/1998 - "Therefore, captopril may delay the development of left ventricular dysfunction and thus the time for corrective surgery."
05/15/1995 - "Studies of Left Ventricular Dysfunction (SOLVD) demonstrated that enalapril therapy significantly improved the clinical course of patients with left ventricular (LV) dysfunction. "
04/15/2007 - "Data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized trial of enalapril versus placebo in patients with ejection fractions <or=35%, were analyzed. "
11/01/2005 - "The rate of new-onset AF in patients with left ventricular dysfunction and mild to moderate HF enrolled in the SoLVD trials was significantly lower with enalapril than with placebo (5.4% vs 24% over 2.9 years, P < .0001). "
12/01/2003 - "Comparing survivors, enalapril generated annual cost savings greater than the average wholesale price of the drug at Studies of Left Ventricular Dysfunction mean dosage levels. "
05/31/2003 - "In the studies of left ventricular dysfunction (SOLVD), enalapril reduced mortality in patients with symptomatic but not asymptomatic left ventricular systolic dysfunction during the trial. "
|6.||carvedilol (Coreg)FDA LinkGeneric
08/01/2012 - "The present study investigated the possible protective role of carvedilol on ADR-induced left ventricular dysfunction in children with ALL. "
01/01/2011 - "We performed a post hoc analysis of pooled individual patient data (n=4217) from 2 multinational, double-blinded, placebo-controlled, randomized trials, CAPRICORN (Carvedilol Postinfarct Survival Control in Left Ventricular Dysfunction Study) and COPERNICUS (Carvedilol Prospective Randomized, Cumulative Survival study). "
02/15/2005 - "The antiarrhythmic effect of carvedilol was examined in a placebo-controlled multicenter trial, the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) study, which enrolled 1,959 patients with reduced left ventricular systolic function after AMI, 98% of whom were treated with an ACE inhibitor. "
05/06/2004 - "Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN)."
01/01/2003 - "All-cause mortality was reduced in patients who received carvedilol in addition to conventional therapy compared with those who received placebo plus conventional therapy in the Carvedilol Post-Infarct Survival Control in LV Dysfunction (CAPRICORN) trial (enrolling 1959 patients with left ventricular dysfunction following acute MI). "
|7.||eplerenone (Inspra)FDA LinkGeneric
07/03/2003 - "Eplerenone in patients with left ventricular dysfunction."
07/03/2003 - "Eplerenone in patients with left ventricular dysfunction."
07/03/2003 - "Eplerenone in patients with left ventricular dysfunction."
05/01/2005 - "Eplerenone has similarly demonstrated significant benefits in experimental animals and in patients with left ventricular dysfunction after myocardial infarction. "
10/01/2004 - "Recent data showed that in rats with left ventricular dysfunction after extensive myocardial infarction, eplerenone on top of ACE inhibition more effectively improved cardiac remodeling and molecular alterations than ACE inhibition alone."
|8.||Brain Natriuretic Peptide (Natrecor)FDA Link
11/01/2011 - "The inclusion of B-type natriuretic peptide with traditional risk scores may be helpful in predicting risk and asymptomatic left ventricular dysfunction in high-risk Hispanics. "
09/01/2004 - "In June 2004, a group of investigators who helped establish the natriuretic peptide treatment paradigm, met to discuss the potential role of nesiritide as an outpatient treatment option for patients with symptomatic HF who were at high risk for repeated admissions, a syndrome now described as "chronic decompensated HF." This report presents their considerations on the contribution of natriuretic peptide physiology to the amelioration of progressive left ventricular dysfunction, the therapeutic use of B-type natriuretic peptide, and its potential application to the outpatient management of acute and chronic decompensated HF. "
02/13/2007 - "Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial."
08/01/2003 - "This study sought to investigate whether the presence of right ventricular systolic dysfunction with pre-existing left ventricular systolic dysfunction is associated with higher plasma brain natriuretic peptide (BNP) levels, compared with patients with isolated left ventricular dysfunction. "
01/01/2001 - "Studies have shown that brain natriuretic peptide (BNP) gene expression is rapidly induced in the infarcted heart and that plasma BNP levels reflect the degree of left ventricular dysfunction. "
02/01/2009 - "Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials."
08/01/2004 - "Two major prospective trials, including one in which patients routinely received ACE inhibitor and beta blocker therapy, have shown that the use of an aldosterone blocker significantly reduces all-cause mortality, sudden cardiovascular death and hospitalisation in patients with acute or chronic left ventricular dysfunction or CHF. "
08/18/2009 - "Review: Aldosterone blockade reduces mortality in patients with left ventricular dysfunction."
10/14/2003 - "Aldosterone blockade in patients with systolic left ventricular dysfunction."
02/01/2008 - "Aldosterone blockade also may be beneficial in patients who have New York Heart Association class II heart failure, asymptomatic left ventricular dysfunction, and heart failure with preserved or normal left ventricular function. "
|10.||Amiodarone (Amiodarona)FDA LinkGeneric
03/11/1999 - "A practical consequence of amiodarone trials is that this drug can be used rather safely in patients with left ventricular dysfunction of any etiology as, in contrast to some class I agents, it does not increase mortality. "
09/01/1998 - "Unlike other antiarrhythmic class I drugs, amiodarone showed in preliminary studies, benefits also in patients with left ventricular dysfunction. "
08/01/1996 - "The results of this study suggest that intravenous amiodarone can be used with appropriate observation to control arrhythmias, regardless of the degree of left ventricular dysfunction."
12/01/2014 - "Rhythm control with amiodarone is associated with comparable hospitalization and mortality rates to rate control in patients with and without left ventricular dysfunction."
12/01/2014 - "Adjusted all-cause and cardiovascular mortality rates were similar with amiodarone versus rate control overall and in subgroups with and without severe left ventricular dysfunction. "
|1.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
11/01/1993 - "Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state."
08/01/1996 - "Our experience suggests that patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting may benefit from preoperative intraaortic balloon pump insertion, especially patients in functional class III or IV. This approach improved survival significantly, reduced hospital stay, and was more cost-effective."
08/01/2012 - "This study evaluated the safety and efficacy of this drug for cases of coronary artery bypass grafting (CABG) with left ventricular dysfunction. "
10/01/2014 - "In patients with left ventricular dysfunction, coronary artery bypass grafting can be performed safely with improvement in quality of life and in left ventricular ejection fraction."
09/01/2007 - "Coronary artery bypass grafting in patients with poor left ventricular dysfunction improved myocardial function. "
03/01/1980 - "Although 22 (79%) of the 28 grafts were patent, there was no significant improvement in resting left ventricular dysfunction as assessed by ejection fraction, left ventricular volume or left ventricular end-diastolic pressure. "
10/01/2007 - "CABG in patients with left ventricular dysfunction was effective, with favorable early graft patency rates. "
05/01/2008 - "Eight (24%) patients recovered completely, 10 (30%) died, 2 (6%) underwent heart transplants, and 13 (39%) were left with persistent left ventricular dysfunction. "
01/01/1995 - "He was placed on the cardiac transplant list because of severe left ventricular dysfunction but was later removed because his symptoms and function improved. "
05/01/1976 - "Thus, hemodynamic evidence of ischemic left ventricular dysfunction during stress may identify those patients who will show objective improvement in ventricular performance after bypass graft surgery."
|3.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
11/12/2009 - "Combined resynchronisation and implantable defibrillator therapy is not cost-effective for left ventricular dysfunction. "
10/01/2014 - "Since several large trials have proven the effectiveness of implantable cardioverter-defibrillators (ICDs) in patients with left ventricular dysfunction, disadvantages have become more apparent. "
08/01/2012 - "Although clinical trials evaluating therapy with implantable cardioverter defibrillators (ICD) have had clear limitations, there are few interventions in which multiple trial settings over a long period have consistently produced a 20% to 30% reduction in total mortality in patients with left ventricular dysfunction. "
11/03/2007 - "Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials."
12/01/2006 - "Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2-5 years. "
|4.||Cardiac Resynchronization Therapy
10/01/2015 - "The aim of the present study was to determine the mechanism of this improved coronary conduit and, in addition, to explore the possible benefits with biventricular pacing in patients with and without severe left ventricular dysfunction. "
05/01/2002 - "Biventricular pacing results in improved hemodynamics and a decrease in SNA compared with intrinsic conduction in patients with left ventricular dysfunction and IVCD. "
07/01/2014 - "In this study we sought to determine factors leading to late left ventricular dysfunction and the impact of cardiac resynchronization as a primary and secondary (upgrade) mode of pacing. "
12/01/2013 - "The Biventricular Pacing After Cardiac Surgery trial investigates hemodynamics of temporary pacing in selected patients at risk of left ventricular dysfunction. "
04/01/2013 - "The aim of the study was to combine clinical results from the European Cohort of the REVERSE study and costs associated with the addition of cardiac resynchronization therapy (CRT) to optimal medical therapy (OMT) in patients with mild symptomatic (NYHA I-II) or asymptomatic left ventricular dysfunction and markers of cardiac dyssynchrony in Spain. "
01/01/1987 - "Improved functional results following myocardial revascularization in patients with left ventricular dysfunction."
06/01/1981 - "Improved long-term survival following myocardial revascularization in patients with severe left ventricular dysfunction."
12/01/2013 - "Improvement of left ventricular function after the surgical procedure was better in group II than group I. The on-pump beating-heart technique is the preferred method for myocardial revascularization in patients with left ventricular dysfunction. "
01/01/2010 - "On-pump beating heart technique can be used in myocardial revascularization among patients with left ventricular dysfunction. "
01/01/2010 - "Myocardial revascularization using on-pump beating heart among patients with left ventricular dysfunction."